Payment overview · 2025
General Payments
$18,185.78
90 reported records · 23 companies
Healthcare provider profile · identity verified
James Y Lin, DO
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · ERIE, PA · NPI 1164599155
Verified facts
What the public records show
CMS Open Payments records show James Y Lin, DO received $18,185.78 in general payments during 2025 across 90 reported records.
Organogenesis Inc. accounted for 58.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 324 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $10,707.37 | 58.9% | 23 | 2025 |
| Reapplix Inc. | Unresolved — no canonical attribution shown | $5,702.75 | 31.4% | 6 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $417.50 | 2.3% | 15 | 2025 |
| MERZ NORTH AMERICA, INC. | Unresolved — no canonical attribution shown | $246.79 | 1.4% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $153.07 | 0.8% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $132.85 | 0.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $130.48 | 0.7% | 5 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $130.42 | 0.7% | 7 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $117.50 | 0.7% | 1 | 2025 |
| Urgo Medical North America, LLC | Unresolved — no canonical attribution shown | $78.44 | 0.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$52.05 | 0.3% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $45.99 | 0.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.23 | 0.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $42.77 | 0.2% | 2 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $26.88 | 0.1% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $24.53 | 0.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.40 | 0.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.22 | 0.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $20.95 | 0.1% | 1 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $18.78 | 0.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.67 | 0.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.71 | 0.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.43 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,322.39 | 6 |
| Food and Beverage | $2,461.25 | 76 |
| Travel and Lodging | $402.14 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $10,660.05 | 20 | 2025 |
Source payment records
|
|||||
| 3C Patch Kit - Box Normalized: 3c patch kit box |
Device | Reapplix Inc. | $5,702.75 | 6 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $298.33 | 7 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | MERZ NORTH AMERICA, INC. | $246.79 | 9 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $138.45 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $132.85 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $130.48 | 5 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $122.86 | 5 | 2025 |
Source payment records
|
|||||
| RENASYS TOUCH Normalized: renasys touch |
Device | Smith+Nephew, Inc. | $119.17 | 8 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $117.50 | 1 | 2025 |
Source payment records
|
|||||
| URGOK2 Normalized: urgok2 |
Device | Urgo Medical North America, LLC | $78.44 | 1 | 2025 |
Source payment records
|
|||||
| VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP Normalized: vashe wound solution 250 ml 8 5 fl oz flip top cap |
Device | Urgo Medical North America, LLC | $78.44 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $52.05 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.23 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $42.77 | 2 | 2025 |
Source payment records
|
|||||
| ALLEVYN HEEL 10.5CM X 13.5CM CTN 5 Normalized: allevyn heel 10 5cm x 13 5cm ctn 5 |
Device | Smith+Nephew, Inc. | $39.43 | 1 | 2025 |
Source payment records
|
|||||
| RENASYS GO v2 HOME Normalized: renasys go v2 home |
Device | Smith+Nephew, Inc. | $39.43 | 1 | 2025 |
Source payment records
|
|||||
| CYGNUS DUAL Normalized: cygnus dual |
Medical Supply | Organogenesis Inc. | $30.33 | 1 | 2025 |
Source payment records
|
|||||
| STRAVIX Normalized: stravix |
Biological | Smith+Nephew, Inc. | $28.83 | 1 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| AFFINITY Normalized: affinity |
Medical Supply | Organogenesis Inc. | $10.95 | 1 | 2025 |
Source payment records
|
|||||
| VIA MATRIX Normalized: via matrix |
Medical Supply | Organogenesis Inc. | $6.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
324 | 61 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 802 | 141 |
| Levothyroxine Sodium | Levothyroxine Sodium | 539 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 534 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 511 | 88 |
| Donepezil Hcl | Donepezil Hcl | 415 | 67 |
| Furosemide | Furosemide | 385 | 71 |
| Eliquis | Apixaban | 324 | 61 |
| Potassium Chloride | Potassium Chloride | 305 | 55 |
| Sertraline Hcl | Sertraline Hcl | 304 | 46 |
| Lisinopril | Lisinopril | 288 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 272 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 260 | 52 |
| Gabapentin | Gabapentin | 221 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 204 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 200 | 46 |
| Simvastatin | Simvastatin | 196 | 26 |
| Bumetanide | Bumetanide | 187 | 34 |
| Memantine Hcl | Memantine Hcl | 184 | 30 |
| Famotidine | Famotidine | 182 | 33 |
| Losartan Potassium | Losartan Potassium | 173 | 35 |
| Omeprazole | Omeprazole | 173 | 39 |
| Oxycodone Hcl | Oxycodone Hcl | 151 | 31 |
| Levetiracetam | Levetiracetam | 150 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 148 | 26 |
| Metformin Hcl | Metformin Hcl | 147 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 144 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 140 | 28 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 135 | 135 |
| Pregabalin | Pregabalin | 130 | 17 |
| Xarelto | Rivaroxaban | 129 | 28 |
| Carvedilol | Carvedilol | 124 | 18 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 121 | 20 |
| Buspirone Hcl | Buspirone Hcl | 115 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 22 |
| Tramadol Hcl | Tramadol Hcl | 113 | 29 |
| Trazodone Hcl | Trazodone Hcl | 113 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 21 |
| Lorazepam | Lorazepam | 108 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 21 |
| Baclofen | Baclofen | 104 | 19 |
| Mirtazapine | Mirtazapine | 101 | 18 |
| Atenolol | Atenolol | 99 | 12 |
| Finasteride | Finasteride | 86 | 15 |
| Allopurinol | Allopurinol | 85 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 15 |
| Olanzapine | Olanzapine | 82 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 80 | 11 |
| Jardiance | Empagliflozin | 78 | 14 |
| Nifedipine Er | Nifedipine | 77 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 14 |
| Alendronate Sodium | Alendronate Sodium | 73 | 15 |
| Ozempic | Semaglutide | 67 | 12 |
| Latanoprost | Latanoprost | 65 | 12 |
| Lactulose | Lactulose | 64 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 11 |
| Lamotrigine | Lamotrigine | 58 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 55 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 55 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 28 |
| Warfarin Sodium | Warfarin Sodium | 54 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 51 | 16 |
| Entresto | Sacubitril/Valsartan | 48 | suppressed |
| Ezetimibe | Ezetimibe | 48 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 12 |
| Lacosamide | Lacosamide | 46 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 44 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 44 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Nyamyc | Nystatin | 42 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 42 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Prednisone | Prednisone | 40 | 13 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Meloxicam | Meloxicam | 38 | suppressed |
| Sucralfate | Sucralfate | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 36 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 22 |
| Nadolol | Nadolol | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Cephalexin | Cephalexin | 34 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 25 |
| Divalproex Sodium | Divalproex Sodium | 33 | suppressed |
| Nystatin | Nystatin | 33 | 12 |
| Topiramate | Topiramate | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 26 |
| Celecoxib | Celecoxib | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 26 |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 20 |
| Xifaxan | Rifaximin | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Haloperidol | Haloperidol | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Rexulti | Brexpiprazole | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 26 | suppressed |
| Teflaro | Ceftaroline Fosamil Acetate | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 18 |
| Risperidone | Risperidone | 25 | suppressed |
| Alprazolam | Alprazolam | 24 | suppressed |
| Felbamate | Felbamate | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Admelog | Insulin Lispro | 21 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Nystop | Nystatin | 19 | 13 |
| Permethrin | Permethrin | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Mupirocin | Mupirocin Calcium | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Budesonide | Budesonide | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Oxycontin | Oxycodone Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 15 | suppressed |
| Azithromycin | Azithromycin | 15 | 12 |
| Clozapine | Clozapine | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 15 | suppressed |
| Erythromycin | Erythromycin Base In Ethanol | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Primidone | Primidone | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Cimetidine | Cimetidine | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Morphine Sulfate | Morphine Sulfate | 13 | 11 |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 12 | 12 |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $18,185.78 · 90 records | Organogenesis Inc. | 3C Patch Kit - Box, AFFINITY, ALLEVYN HEEL 10.5CM X 13.5CM CTN 5, AMYVID, AUSTEDO XR, CAPLYTA, CYGNUS DUAL, GRAFIX PL, INSPIRE, INTELLIS ADAPTIVESTIM, KISUNLA, LEQVIO, Leqembi, MOUNJARO, Ozempic, PURAPLY WOUND MATRIX, RENASYS GO v2 HOME, RENASYS TOUCH, REPATHA, REXULTI, REZDIFFRA, SPINRAZA, STRAVIX, URGOK2, VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP, VERQUVO, VIA MATRIX, Xeomin, ZEPBOUND, bio-ConneKt | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error